Since it is conceivable that disruption of the DDR signaling may affect the response to DNA-damaging anticancer therapy (such as cisplatin-based ones), future work should be focused on testing whether and how DDR pathways will be altered upon treatment of cisplatin in the context of manipulating RDM1 functionality in lung adenocarcinoma cells. This evidence concerns the gene RDM1 and lung adenocarcinoma.